Han Dai
CBO and Head of Investment @ Viva BioInnovator
Han Dai is a seed investor at Viva BioInnovator focused on Health Care and Biotechnology. Han Dai is the Head of Viva BioInnovator and Chief Business Officer of Viva Biotech.
- Total investments:
- 2
- Last investment:
- Lead investor:
- 100%
Last updated:
For AI agents: llms.txt
Industries Han Dai invests in
Stages Han Dai invests in
Countries Han Dai invests in
Investment Focus
Industry
- Health Care 2 (100%)
- Biotechnology 2 (100%)
- Medical 1 (50%)
- Therapeutics 1 (50%)
- Pharmaceutical 1 (50%)
Stage
- Seed 1 (50%)
- Series A 1 (50%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Amberstone Biosciences
|
Amberstone Biosciences discovers novel immunotherapies through innovative technologies and creative partnerships.Amberstone's focus is difficult targets requiring a unique mode-of-action and/or particular functional property, which are otherwise challenging for traditional approaches.These conventional limitations are overcome via atwo-pronged approach. First, we have demonstrated success with our microfluidics-powered AmberFlow drug-discovery platform. Second, our team of experts has keen insights in immuno-oncology and ample experience with single-cell assay biology. | $12M / Series A / Jan 03, 2022 | |
Fuse Biotherapeutics
|
Fuse Biotherapeutics is a biotech company developing next-generation immune-modulating therapeutics for patients with cancers. The company's therapeutic approach integrates the multiple steps of an immune response in a rational manner such that potent responses to danger are targeted without sacrificing natural breaks in the system that sparehealthy tissues.Fuse Biotherapeutics was founded in 2021 and is headquartered in Los Angeles, CA. | $9.5M / Seed / Nov 15, 2021 |
Co-Investors
About Viva BioInnovator
Viva BioInnovator (VBI) is the specialized investment and incubation arm of Viva Biotech Holdings. We focus on the initial creation and development of biotech startups across all indications and drug types. During the early stages of drug discovery, we can nurture and accelerate a startup's growth from idea to clinical program. VBI'sunique investment and incubation model started out of necessity in 2014. Our roots are in drug discovery services, where we operate world-leading and proprietary drug discovery platforms. While serving big pharma customers from around the globe, we came to realize the huge demand from many entrepreneurs who have great ideas but cannot receive funding to advance their plan due to lack of data. We saw the value in many of these innovative ideas and provided our CRO drug discovery services, operational support, and monetary backing to help these creative scientists embark on the "0 to 1" transformation. This spark launched our "equity for service (EFS)" investment and incubation model. VBI is based in Shanghai, with an office in Boston and personnel in California. As of early 2019, VBI has invested in over 30 companies out of the hundreds of proposals submitted for review and we plan to invest at a rapid pace in the years to come. The majority of our current portfolio companies are US based, but we are open to proposals globally and are excited to see new ideas that fit our investment strategy. If you would like to learn more about us, please visit: www.vivabioinnovator.com Or send an email to innovation@vivabiotech.com If you would like to learn more about our parent company, Viva Biotech, please visit: www.vivabiotech.com
Viva BioInnovator Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Cheney Mao
Founder, Chairman, CEO
|
|||
|
Han Dai
CBO and Head of Investment
|
|||
3 more contacts available
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Han Dai invest in?
Han Dai invests primarily in Health Care, Biotechnology and Medical startups, most often at Seed and Series A stage. Most of the 2 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Han Dai last invest?
The most recent investment recorded for Han Dai closed in Jan 2022. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
